Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)

Keisuke Shigeta; Takeo Kosaka; Hiroshi Hongo; Yoshinori Yanai; Kazuhiro Matsumoto; Shinya Morita; Ryuichi Mizuno; Toshiaki Shinojima; Eiji Kikuchi; Mototsugu Oya

doi:10.1007/s10147-019-01395-0

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)

Keisuke Shigeta, Takeo Kosaka, Hiroshi Hongo, Yoshinori Yanai, Kazuhiro Matsumoto, Shinya Morita, Ryuichi Mizuno, Toshiaki Shinojima, Eiji Kikuchi, Mototsugu Oya

Department of Urology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the Original Publication, Tables 2 and 3 have been published with “###” instead of numerical values. Also in Table 2, few entries were inadvertently published in bold. The corrected tables are given in this Correction. The errors have been occurred at Publisher’s end. The original article has been corrected.

Original language	English
Pages (from-to)	554-556
Number of pages	3
Journal	International Journal of Clinical Oncology
Volume	24
Issue number	5
DOIs	https://doi.org/10.1007/s10147-019-01395-0
Publication status	Published - 2019 May 15

ASJC Scopus subject areas

Surgery
Hematology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10147-019-01395-0

Fingerprint

Dive into the research topics of 'Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)'. Together they form a unique fingerprint.

Cite this

Shigeta, K., Kosaka, T., Hongo, H., Yanai, Y., Matsumoto, K., Morita, S., Mizuno, R., Shinojima, T., Kikuchi, E., & Oya, M. (2019). Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5). International Journal of Clinical Oncology, 24(5), 554-556. https://doi.org/10.1007/s10147-019-01395-0

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5). / Shigeta, Keisuke; Kosaka, Takeo; Hongo, Hiroshi et al.
In: International Journal of Clinical Oncology, Vol. 24, No. 5, 15.05.2019, p. 554-556.

Research output: Contribution to journal › Comment/debate › peer-review

Shigeta, K, Kosaka, T, Hongo, H, Yanai, Y, Matsumoto, K , Morita, S , Mizuno, R, Shinojima, T, Kikuchi, E & Oya, M 2019, 'Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)', International Journal of Clinical Oncology, vol. 24, no. 5, pp. 554-556. https://doi.org/10.1007/s10147-019-01395-0

Shigeta K, Kosaka T, Hongo H, Yanai Y, Matsumoto K , Morita S et al. Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5). International Journal of Clinical Oncology. 2019 May 15;24(5):554-556. doi: 10.1007/s10147-019-01395-0

Shigeta, Keisuke ; Kosaka, Takeo ; Hongo, Hiroshi et al. / Correction to : Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5). In: International Journal of Clinical Oncology. 2019 ; Vol. 24, No. 5. pp. 554-556.

@article{df7b926977284ba19917843dfbd2de0a,

title = "Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)",

abstract = "In the Original Publication, Tables 2 and 3 have been published with “###” instead of numerical values. Also in Table 2, few entries were inadvertently published in bold. The corrected tables are given in this Correction. The errors have been occurred at Publisher{\textquoteright}s end. The original article has been corrected.",

author = "Keisuke Shigeta and Takeo Kosaka and Hiroshi Hongo and Yoshinori Yanai and Kazuhiro Matsumoto and Shinya Morita and Ryuichi Mizuno and Toshiaki Shinojima and Eiji Kikuchi and Mototsugu Oya",

note = "Publisher Copyright: {\textcopyright} 2019, Japan Society of Clinical Oncology.",

year = "2019",

month = may,

day = "15",

doi = "10.1007/s10147-019-01395-0",

language = "English",

volume = "24",

pages = "554--556",

journal = "International Journal of Clinical Oncology",

issn = "1341-9625",

publisher = "Springer Japan",

number = "5",

}

TY - JOUR

T1 - Correction to

T2 - Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)

AU - Shigeta, Keisuke

AU - Kosaka, Takeo

AU - Hongo, Hiroshi

AU - Yanai, Yoshinori

AU - Matsumoto, Kazuhiro

AU - Morita, Shinya

AU - Mizuno, Ryuichi

AU - Shinojima, Toshiaki

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2019/5/15

Y1 - 2019/5/15

N2 - In the Original Publication, Tables 2 and 3 have been published with “###” instead of numerical values. Also in Table 2, few entries were inadvertently published in bold. The corrected tables are given in this Correction. The errors have been occurred at Publisher’s end. The original article has been corrected.

AB - In the Original Publication, Tables 2 and 3 have been published with “###” instead of numerical values. Also in Table 2, few entries were inadvertently published in bold. The corrected tables are given in this Correction. The errors have been occurred at Publisher’s end. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85062715373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062715373&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01395-0

DO - 10.1007/s10147-019-01395-0

M3 - Comment/debate

C2 - 30826960

AN - SCOPUS:85062715373

SN - 1341-9625

VL - 24

SP - 554

EP - 556

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

IS - 5

ER -

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration (International Journal of Clinical Oncology, (2019), 24, 5, (546-553), 10.1007/s10147-018-01388-5)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this